Akero is developing weekly injectable efruxifermin for MASH with solid 96-week efficacy data and three Phase III studies underway. But will it find a treatment niche in a competitive space?

While injectables have had all the limelight, some analysts see a bright future for Sagimet’s oral denifanstat, potentially as a backbone therapy in combination with other treatments for MASH.

Survodutide burnishes its best-in-class MASH case with a 64% improvement in moderate-to advanced fibrosis at Phase II, but tolerability an issue

An important mid-stage trial succeeds, but an odd finding on the fibrosis endpoint will spur close examination of Lilly’s incretin.